SK282118B6 - Použitie antagonistu hormónu uvoľňujúceho gonadotropíny - Google Patents

Použitie antagonistu hormónu uvoľňujúceho gonadotropíny Download PDF

Info

Publication number
SK282118B6
SK282118B6 SK70-97A SK7097A SK282118B6 SK 282118 B6 SK282118 B6 SK 282118B6 SK 7097 A SK7097 A SK 7097A SK 282118 B6 SK282118 B6 SK 282118B6
Authority
SK
Slovakia
Prior art keywords
estrogen
dose
treatment
gnrh
antagonist
Prior art date
Application number
SK70-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK7097A3 (en
Inventor
Gary D. Hodgen
Audrey Philips
Original Assignee
The Medical College Of Hampton Roads
Ortho Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282118(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by The Medical College Of Hampton Roads, Ortho Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads
Publication of SK7097A3 publication Critical patent/SK7097A3/sk
Publication of SK282118B6 publication Critical patent/SK282118B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK70-97A 1994-07-22 1995-07-18 Použitie antagonistu hormónu uvoľňujúceho gonadotropíny SK282118B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
SK7097A3 SK7097A3 (en) 1997-11-05
SK282118B6 true SK282118B6 (sk) 2001-11-06

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
SK70-97A SK282118B6 (sk) 1994-07-22 1995-07-18 Použitie antagonistu hormónu uvoľňujúceho gonadotropíny

Country Status (29)

Country Link
EP (1) EP0769956B1 (de)
JP (1) JP3138477B2 (de)
CN (1) CN1137722C (de)
AP (1) AP775A (de)
AT (1) ATE190494T1 (de)
AU (1) AU691952B2 (de)
BG (1) BG63363B1 (de)
BR (1) BR9508718A (de)
CA (1) CA2195745C (de)
CY (1) CY2228B1 (de)
CZ (1) CZ291803B6 (de)
DE (1) DE69515666T2 (de)
DK (1) DK0769956T3 (de)
EE (1) EE03515B1 (de)
ES (1) ES2145286T3 (de)
FI (1) FI970244A (de)
GR (1) GR3033590T3 (de)
HU (1) HU218910B (de)
IL (1) IL114655A (de)
IS (1) IS4413A (de)
LV (1) LV11823B (de)
MX (1) MX9700574A (de)
NO (1) NO970257L (de)
NZ (1) NZ290554A (de)
OA (1) OA10730A (de)
PT (1) PT769956E (de)
RU (1) RU2181598C2 (de)
SK (1) SK282118B6 (de)
WO (1) WO1996003138A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
KR100772852B1 (ko) * 1999-09-23 2007-11-02 젠타리스 게엠베하 자궁내막증 치료용 약제학적 조성물
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (de) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
WO2009145690A1 (en) * 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CZ15097A3 (en) 1997-11-12
PT769956E (pt) 2000-07-31
IL114655A0 (en) 1995-11-27
FI970244A0 (fi) 1997-01-21
ATE190494T1 (de) 2000-04-15
CZ291803B6 (cs) 2003-06-18
JP3138477B2 (ja) 2001-02-26
CN1200674A (zh) 1998-12-02
EP0769956A1 (de) 1997-05-02
EP0769956B1 (de) 2000-03-15
EE03515B1 (et) 2001-10-15
AU3132095A (en) 1996-02-22
LV11823B (en) 1998-03-20
DK0769956T3 (da) 2000-06-05
HU218910B (hu) 2000-12-28
NO970257D0 (no) 1997-01-21
BR9508718A (pt) 1997-12-30
AP9700913A0 (en) 1997-01-31
RU2181598C2 (ru) 2002-04-27
JPH10503203A (ja) 1998-03-24
CA2195745C (en) 2005-03-29
NZ290554A (en) 2000-08-25
IS4413A (is) 1997-01-14
ES2145286T3 (es) 2000-07-01
BG63363B1 (bg) 2001-11-30
HUT77127A (hu) 1998-03-02
FI970244A (fi) 1997-01-21
SK7097A3 (en) 1997-11-05
WO1996003138A1 (en) 1996-02-08
DE69515666D1 (de) 2000-04-20
DE69515666T2 (de) 2000-07-06
CY2228B1 (en) 2003-04-18
HU9700046D0 (en) 1997-02-28
LV11823A (lv) 1997-08-20
BG101158A (en) 1997-09-30
AU691952B2 (en) 1998-05-28
MX9700574A (es) 1997-12-31
AP775A (en) 1999-10-28
NO970257L (no) 1997-01-21
EP0769956A4 (de) 1999-03-10
GR3033590T3 (en) 2000-09-29
OA10730A (en) 2001-06-07
EE9700208A (et) 1998-02-16
IL114655A (en) 2005-08-31
CN1137722C (zh) 2004-02-11
CA2195745A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
EP0785792B1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
KR100248857B1 (ko) 호르몬 대체치료
US7309691B2 (en) Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders
SK282118B6 (sk) Použitie antagonistu hormónu uvoľňujúceho gonadotropíny
RU2360681C2 (ru) Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Bromer et al. Medical treatment options for leiomyomas
Gordon et al. GnRH Antagonists: Primate Models for Clinical Indications

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100718